Key Highlights:
- SOPHiA Genetics partners with AstraZeneca for innovative liquid biopsy tools.
- Analysts predict an average price target of $6.80 for SOPH, a substantial upside.
- SOPHiA Genetics holds an "Outperform" consensus rating from brokerage firms.
SOPHiA Genetics (NASDAQ: SOPH) continues to make strides in the biotech industry by expanding its partnership with AstraZeneca. This collaboration aims to accelerate the deployment of a state-of-the-art liquid biopsy testing tool. By utilizing SOPHiA DDM’s sophisticated algorithms, this application significantly enhances the ability to analyze circulating tumor DNA from a blood sample, thus offering crucial support in monitoring cancer and refining treatment decisions.
Wall Street Analysts' Forecast
Analysts show optimism for Sophia Genetics SA (SOPH, Financial), with an average one-year price target of $6.80. Their assessments range from a low estimate of $5.00 to a high estimate of $11.00. Given the current price of $3.31, this average target represents a striking 105.53% upside potential. For more in-depth estimates, visit the Sophia Genetics SA (SOPH) Forecast page.
The sentiment from 6 brokerage firms culminates in an average brokerage recommendation score of 1.8 for SOPHiA Genetics SA (SOPH, Financial), categorizing it as "Outperform." This rating scale ranges from 1, indicating a Strong Buy, to 5, signaling Sell.
According to GuruFocus metrics, the estimated GF Value of Sophia Genetics SA (SOPH, Financial) in a year is projected to be $5.48. This estimate suggests a promising 65.63% upside from the current price of $3.3085. The GF Value reflects GuruFocus’ assessment of the stock's fair value, derived from historical trading multiples, past business growth, and forecasted future performance. Find more comprehensive data on the Sophia Genetics SA (SOPH) Summary page.
